Tebentafusp

Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen) . Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells[1][2].

Product Specifications

CAS Number

[1874157-95-5]

Product Name Alternative

IMCgp100

UNSPSC

12352203

Target

Interleukin Related; TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tebentafusp.html

Purity

99.90

Solubility

10 mM in DMSO

Smiles

[Tebentafusp]

Molecular Weight

(76.16 kDa)

References & Citations

[1]Middleton MR, et al. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clin Cancer Res. 2020 Nov 15;26 (22) :5869-5878. |[2]Dhillon S. Tebentafusp: First Approval. Drugs. 2022 Apr;82 (6) :703-710. |[3]Boudousquie C, et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells. Immunology. 2017 Nov;152 (3) :425-438. |[4]Baeuerle P A, et al. Passive immunotherapy by T cell–engaging bispecifi c antibodies[M]//Cancer Vaccines. CRC Press, 2015: 266-278.